Is imiquimod a promising drug to treat oral mucosa diseases? A scoping review and new perspectives

Imiquimod (IMQ) is a chemotherapeutic and immunostimulant drug that is applied topically, demonstrating antitumor and antiviral activities. The objective of this review was to compile data on the off‐label use of IMQ in oral mucosal diseases. IMQ has exhibited effectiveness in the treatment of vario...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2024-02, Vol.90 (2), p.427-439
Main Authors: Mello Palma, Victor, Frank, Luiza Abrahão, Balinha, Daiana Moraes, Rados, Pantelis Varvaki, Pohlmann, Adriana Raffin, Guterres, Silvia Stanisçuaski, Visioli, Fernanda
Format: Article
Language:English
Subjects:
imiquimod
off‐label use
oral diseases
oral mucosa
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Imiquimod (IMQ) is a chemotherapeutic and immunostimulant drug that is applied topically, demonstrating antitumor and antiviral activities. The objective of this review was to compile data on the off‐label use of IMQ in oral mucosal diseases. IMQ has exhibited effectiveness in the treatment of various oral mucosal conditions, including oral carcinogenic lesions, neoplasms, HPV‐related lesions and autoimmune disorders. Although IMQ holds promise as a potential strategy for addressing oral mucosal lesions, it is important to note that significant side effects have been frequently reported. Nonetheless, it is crucial to develop and test new technological systems, such as the combination of nanotechnology with innovative drug delivery platforms. These advancements aim to minimize side effects and prolong the drug's contact time with the mucosa, preventing its removal by salivary flow.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.15923